4-phenylbutyrate
Cholestasis, Intrahepatic
Children's Hospital of Fudan UniversityPhase 2/3Active
CCC
55/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 40/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Cholestasis, Intrahepatic cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Linerixibat GlaxoSmithKline | Phase 2 | B |
URSODEOXYCHOLIC ACID GlaxoSmithKline | Phase 2 | B |
Same molecule, other indications
4-phenylbutyrate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →